CTRI/2024/04/065700进行中（未招募）4 期
An Open Label Study to Evaluate the Efficacy and Safety of an Ayurvedic Water Based Juice Formulation on Weight Management in Healthy Volunteers - NI
Sesa Care Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Subjects of either sex between 25 to 45 years of age.
- •2)Subject with BMI range (26-32).
- •3)Ability of the subject to understand the risks/benefits of the protocol
- •4)Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, or double-barrier and have a negative pregnancy test at the Screening Visit. Female subjects of non-childbearing potential must be amenorrhoeic for at least one year or had a hysterectomy and/or bilateral oophorectomy.
- •5)Willingness to participate in a walking-exercise program (5 days a week, 30 min per day) with the scheduled timing per week during the course of the study.
- •6)Subject agrees to consume a vegetarian/non-vegetarian diet of approximately 2,000 kcal/day (17% protein, 25% Fat and 58% carbohydrate).
- •7)Subjects willing to go for DEXA analysis during the study.
- •8)Subjects willing to get photographed from front and side pose in similar or preferably same set of clothes before and after study. Subject anonymity will be maintained in photographs with an eye strip.
- •9)Subject should be available for duration of study period (three months).
- •10)Subjects agree to come to site in fasting state for their weight measurements and other laboratory parameters examination in all the scheduled visits.
- •11)Subject using other therapies for weight management including physiotherapy/ occupational therapy agrees to discontinue these therapies during this study.
- •12)Subject agrees not to start any new therapies for weight loss during the study.
- •13)Subjects agree to maintain the activity dairy
- •14)Willing to give written informed consent and willing to comply with trial protocol.
排除标准
- •1)Subjects suffered from intractable obesity, had defined weight limits or had experienced any recent, unexplained weight loss or gain.
- •2)Subjects having history of underlying inflammatory arthropathy, septic arthritis, gout, inflammatory joint disease, joint fracture or rheumatoid arthritis.
- •3)Subjects with hyperuricemia, thyroid disease, abnormal values of liver or kidney functioning or abnormal findings on complete blood count, and hypertension.
- •4)Subject with hyperuricemia, thyroid disease, abnormal liver or kidney function test, abnormal findings on complete blood count, and hypertension.
- •5)Subjects having history of asthma, cardiovascular diseases, coagulopathies, diabetes except other than the subject having the pre-diabetes condition with the fasting blood glucose or random blood glucose = 140-199 mg/dl.
- •6)Subjects having history of high alcohol intake.
- •7)Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent and increase the risk of adverse events or interfere with study assessments.
- •8)Subjects, who are pregnant, breast feeding or planning to become pregnant during the study.
- •9)Immunocompromised subjects or subjects with steroids or immunomodulators.
- •10)Patients of vulnerable group.
- •11)Any other condition that, in the opinion of the investigator, would adversely affect the subject’s ability to complete the study or its measures.
- •12)Subjects participated in any investigational study medication within thirty 30 days prior to screening.
- •13)Subjects known allergy to compounds of investigational product.
研究者
相似试验
已完成
不适用
A clinical trial to assess the Efficacy and Safety of LPOTC001-11 versus Colgate Plax in dental plaques and gingivitisCTRI/2012/02/002460aila Pharmaceuticals Pvt Ltd40
未知
3 期
An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/r/ABT-267 Co-administered With Ribavirin for 12 or 16 Weeks in Treatment-Naive and Treatment-Experienced Japanese Adults With Genotype 2 Chronic HCV Infection With and Without Compensated Cirrhosis (GIFT-II)JPRN-jRCT2080222382AbbVie GK
招募中
3 期
Phase 3 study to Evaluate the Efficacy and Safety of Avatrombopag in Japanese Adults with Chronic Immune ThrombocytopeniaChronic Immune ThrombocytopeniaJPRN-jRCT2031220005Shimizu Yasuko19
进行中（未招募）
1 期
A study to look at the efficacy and safety of an investigational drug, revusiran, in the treatment of patients with Transthyretin-Mediated amyloidosis, whose disease has continued to worsen following liver transplantatioEUCTR2015-002603-29-ESAlnylam Pharmaceuticals, Inc12
进行中（未招募）
1 期
A study to look at the efficacy and safety of an investigational drug, revusiran, in the treatment of patients with Transthyretin-Mediated amyloidosis, whose disease has continued to worsen following liver transplantatioTransthyretin (TTR)-mediated Familial Amyloidotic Polyneuropathy (FAP)MedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002603-29-PTAlnylam Pharmaceuticals, Inc12